

University of Groningen

## PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy

Rybalov, Maxim; Ananias, Hildo J. K.; Hoving, Hilde D.; van der Poel, Henk G.; Rosati, Stefano; de Jong, Igle J.

*Published in:*  
International Journal of Molecular Sciences

*DOI:*  
[10.3390/ijms15046046](https://doi.org/10.3390/ijms15046046)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2014

[Link to publication in University of Groningen/UMCG research database](#)

### *Citation for published version (APA):*

Rybalov, M., Ananias, H. J. K., Hoving, H. D., van der Poel, H. G., Rosati, S., & de Jong, I. J. (2014). PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy. *International Journal of Molecular Sciences*, 15(4), 6046-6061.  
<https://doi.org/10.3390/ijms15046046>

### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Article

## PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy

Maxim Rybalov <sup>1,†</sup>, Hildo J. K. Ananias <sup>1,†</sup>, Hilde D. Hoving <sup>1</sup>, Henk G. van der Poel <sup>2</sup>, Stefano Rosati <sup>3</sup> and Igle J. de Jong <sup>1,\*</sup>

<sup>1</sup> Department of Urology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, Groningen 9700 RB NL, The Netherlands; E-Mails: maxrybalov@mail.ru (M.R.); h.j.k.ananias@umcg.nl (H.J.K.A.); h.d.hoving@umcg.nl (H.D.H.)

<sup>2</sup> Department of Urology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands; E-Mail: h.vd.poel@nki.nl

<sup>3</sup> Department of Pathology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, Groningen 9700 RB NL, The Netherlands; E-Mail: s.rosati@umcg.nl

<sup>†</sup> These authors contributed equally to this work.

\* Author to whom correspondence should be addressed; E-Mail: i.j.de.jong@umcg.nl; Tel.: +31-50-361-23-80; Fax: +31-50-361-96-07.

Received: 24 January 2014; in revised form: 28 March 2014 / Accepted: 28 March 2014 /

Published: 10 April 2014

---

**Abstract:** In this retrospective pilot study, the expression of the prostate-specific membrane antigen (PSMA), the epithelial cell adhesion molecule (EpCAM), the vascular endothelial growth factor (VEGF) and the gastrin-releasing peptide receptor (GRPR) in locally recurrent prostate cancer after brachytherapy or external beam radiotherapy (EBRT) was investigated, and their adequacy for targeted imaging was analyzed. Prostate cancer specimens were collected of 17 patients who underwent salvage prostatectomy because of locally recurrent prostate cancer after brachytherapy or EBRT. Immunohistochemistry was performed. A pathologist scored the immunoreactivity in prostate cancer and stroma. Staining for PSMA was seen in 100% (17/17), EpCAM in 82.3% (14/17), VEGF in 82.3% (14/17) and GRPR in 100% (17/17) of prostate cancer specimens. Staining for PSMA, EpCAM and VEGF was seen in 0% (0/17) and for GRPR in 100% (17/17) of the specimens' stromal compartments. In 11.8% (2/17) of cases, the GRPR staining intensity of prostate cancer was higher than stroma, while in 88.2% (15/17), the staining was equal. Based on the absence of stromal staining, PSMA, EpCAM and VEGF show high tumor

distinctiveness. Therefore, PSMA, EpCAM and VEGF can be used as targets for the bioimaging of recurrent prostate cancer after EBRT to exclude metastatic disease and/or to plan local salvage therapy.

**Keywords:** prostate cancer; immunohistochemistry; PSMA; EpCAM; VEGF; GRPR

---

## 1. Introduction

Prostate cancer is the most commonly diagnosed cancer among men, and its incidence rates remain as the highest in many regions of the world [1]. About 18% of patients with localized disease develop a prostate-specific antigen (PSA) recurrence within five years after brachytherapy and external beam radiotherapy (EBRT) with doses higher than 72 Gy. This is in contrast to 49% of patients who were treated with doses less than 72 Gy [2]. At present, there is no imaging modality that can accurately discriminate between locally and distant recurrent prostate cancer after treatment with curative intent. Selecting patients for salvage cryotherapy of the prostate or salvage prostatectomy by excluding distant metastases proves a diagnostic challenge.

New diagnostic techniques are needed to improve the imaging of recurrent prostate cancer. Furthermore, although early-stage and locally recurrent prostate cancer can be cured, treatment of metastasized disease is currently only palliative, making it important for new therapeutic applications to be devised [3].

Significant expression of certain antigens in prostate cancer as compared to normal tissue could be used for antigen-targeted imaging or therapy. Numerous pre-clinical and clinical trials focused on this topic have already shown promising results [4–8].

Among the antigens used for diagnostic applications, the prostate-specific membrane antigen (PSMA) was demonstrated to be a useful target [9–13]. PSMA is a Type II integral membrane glycoprotein, which is overexpressed in prostate cancer in comparison to benign prostate tissue [11,14,15]. Next to expression in prostate, PSMA was found to be expressed in the neovasculature of solid tumors in comparison to normal vasculature [16,17]. The biological role of PSMA is not completely understood [10,18,19].

Ross *et al.* demonstrated a significant correlation between PSMA expression in prostate cancer and the Gleason score, pathological stage and biochemical recurrence [11]. Indium-111 capromab pendetide (ProstaScint®) is a radiolabelled antibody directed against PSMA. Correlation of scan results with pathological specimens suggests that ProstaScint is able to detect soft tissue metastases [20–23]. However, for routine use in clinical practice, the sensitivity of ProstaScint is not high enough, because the antibody targets the intracellular epitope of PSMA, thereby probably targeting only damaged or necrotic/apoptotic cells. Furthermore, the role of ProstaScint in the diagnosis of recurrent disease has to be elucidated [24].

Another antigen that can be used as an imaging target is the epithelial cell adhesion molecule (EpCAM). EpCAM is a transmembrane glycoprotein, which is highly expressed in rapidly proliferating tumors of epithelial origin [25–27]. This protein is found to be strongly expressed in several carcinomas [28–31]. In normal epithelium, there is a lower expression of EpCAM [32]. EpCAM mediates epithelial-specific

intercellular cell-adhesion. Next, it is suggested that EpCAM is involved in cell migration, signaling, proliferation and differentiation [33]. The expression of EpCAM is inversely related to prognosis in several carcinomas [33]. For prostate cancer, this relation is controversial [32,34].

Signal protein vascular endothelial growth factor (VEGF) and its receptors are involved in (tumor-related) angiogenesis [35,36]. VEGF is overexpressed in a variety of tumors, including gliomas, breast, renal cell and hepatocellular cancer [37]. VEGF is a potential target, as its expression has also been demonstrated in prostate cancer [38,39]. The expression of VEGF in normal prostate, benign prostate hyperplasia and prostate cancer in relation to tumor grade is inconsistent in the current literature [7,40–49]. As for EpCAM, the prognostic value of VEGF expression is controversial [50–53].

The gastrin-releasing peptide receptor (GRPR) can be a promising imaging target. GRPR is a glycosylated seven-transmembrane G-protein coupled receptor, which is expressed in numerous cancers, such as those of the lung, colon and prostate [54–59]. GRPR seems to be overexpressed in prostate cancer in comparison to sparse expression in normal prostate tissue [60–62]. Binding of GRPR stimulates the growth of prostate cancer cells *in vitro* and *in vivo* [63,64]. A significant inverse correlation was found between GRPR expression and an increasing Gleason score [60].

Currently, there is no knowledge about the expression of PSMA, EpCAM, VEGF and GRPR in locally recurrent prostate cancer after brachytherapy or external beam radiotherapy. Therefore, the aim of this pilot study was to investigate the expression of these antigens using immunohistochemistry and to analyze their potency for new diagnostic applications in locally recurrent prostate cancer.

## 2. Results and Discussion

### 2.1. Results

In Table 1, the results of the immunohistochemical staining of different antibodies in prostate cancer specimens are presented.

**Table 1.** Gleason sum scores, therapy characteristics and staining intensities of the antibodies in the salvage prostatectomy specimens.

Patient No.	Radiotherapy (Dose in Gy)	Hormonal Status Prior to Salvage Prostatectomy	Interval between Radiotherapy and Salvage Prostatectomy (Months)	Stage	Gleason	PSMA	EpCAM	VEGF	GRPR
1	EBRT (Dose unknown)	LHRH + AA	51	pT3b	7	++	+	++	+++
2	Brachytherapy (HDR)	None	45	pT2c	8	+	++	++	+++
3	EBRT (70)	LHRH + AA	58	pT3b	8	+	-	+	+++
4	EBRT (70)	None	24	pT3a	7	+	+	-	++
5	EBRT (Dose unknown)	None	80	pT2c	7	++	+	-	+
6	Brachytherapy (LDR)	None	47	pT2c	cnd	+	+	-	+++
7	EBRT (70)	LHRH + AA	120	pT3a	7	+++	-	+	+
8	EBRT (66)	None	31	pT3b	8	+	-	+	+

Table 1. Cont.

Patient No.	Radiotherapy (Dose in Gy)	Hormonal Status Prior to Salvage Prostatectomy	Interval between Radiotherapy and Salvage Prostatectomy (Months)	Stage	Gleason	PSMA	EpCAM	VEGF	GRPR
9	EBRT (66)	None	78	pT4	7	+++	+++	+	+++
10	EBRT (66)	None	48	pT3b	8	+++	++	++	+++
11	EBRT (Dose unknown)	Unknown	63	pT3b	7	+++	+++	+++	++
12	Brachytherapy (LDR)	None	41	pT4	7	+++	+++	+	++
13	EBRT (70)	None	49	pT3a	8	+	++	++	++
14	EBRT (68)	LHRH	58	pT3a	6	+++	+++	++	+++
15	Brachytherapy (LDR)	AA	88	pT3b	8	+++	++	++	+++
16	EBRT (68)	None	13	pT3b	6	+	++	+	++
17	EBRT (70)	LHRH	34	pT3b	10	+++	++	+	++

cnd, could not be determined; EBRT, external beam radiotherapy; HDR, high dose rate; LDR, low dose rate; LHRH, luteinizing-hormone-releasing hormone agonist; AA, androgen receptor antagonist.

Overall, staining for PSMA was seen in 100% (17/17), EpCAM in 82.3% (14/17), VEGF in 82.3% (14/17) and GRPR in 100% (17/17) of prostate cancer specimens. Staining for PSMA, EpCAM and VEGF was seen in 0% (0/17) and for GRPR in 100% (17/17) of the specimens' stromal compartments. Immunohistochemical staining intensity frequency, number and percent are shown in Table 2.

Table 2. Immunohistochemical staining intensity of prostate cancer and stroma.

Staining Intensity	PSMA Prostate Cancer	PSMA Stroma	EpCAM Prostate Cancer	EpCAM Stroma	VEGF Prostate Cancer	VEGF Stroma	GRPR Prostate Cancer	GRPR Stroma
0	0 (0%)	17 (100%)	3 (17.7%)	17 (100%)	3 (17.7%)	17 (100%)	0 (0%)	0 (0%)
1+	7 (41.2%)	-	4 (23.5%)	-	7 (41.2%)	-	3 (17.7%)	3 (17.7%)
2+	2 (11.8%)	-	6 (35.3%)	-	6 (35.3%)	-	6 (35.3%)	8 (47.0%)
3+	8 (47.0%)	-	4 (23.5%)	-	1 (5.8%)	-	8 (47.0%)	6 (35.3%)
Overall+	17/17 (100%)	0/17 (0%)	14/17 (82.3%)	0/17 (0%)	14/17 (82.3%)	0/17 (0%)	17/17 (100%)	17/17 (100%)

In 11.8% (2/17) of cases, the GRPR staining intensity of prostate cancer was higher than that of stroma. In 88.2% (15/17) of cases, the GRPR staining intensity of prostate cancer was equal to the staining intensity of stroma. Tumor distinctiveness is shown in Table 3.

Table 3. Tumor distinctiveness.

Tumor distinctiveness	PSMA	EpCAM	VEGF	GRPR
0	-	3 (17.7%)	3 (17.7%)	15 (88.2%)
1	7 (41.2%)	4 (23.5%)	7 (41.2%)	2 (11.8%)
2	2 (11.8%)	6 (35.3%)	6 (35.3%)	-
3	8 (47.0%)	4 (23.5%)	1 (5.8%)	-


Tumor distinctiveness = staining intensity tumor – staining intensity stroma.




## 2.2. Staining Pattern

PSMA staining in prostate cancer specimens was membranous and cytoplasmic (Figure 1). Six cases with focal uptake amidst negative cancer tissue were observed (Patient No. 2–4, 6, 8, 13) (Figure 1). For PSMA, there was minimal staining of prostatic intraepithelial neoplasia (PIN) and normal prostate epithelium. EpCAM stained cytoplasm and at the basal membrane (Figure 2). VEGF and GRPR staining in prostate cancer tissue was cytoplasmic and diffuse (Figures 3 and 4). Staining of striated muscle was observed for GRPR.

**Figure 1.** PSMA staining in prostate cancer tissue. (a) Membranous and cytoplasmic brown staining for PSMA in prostate cancer cells, 400× magnification; (b) focal brown staining for PSMA in prostate cancer cells (arrows) amidst negative cancer tissue (\*), 200× magnification.




**Figure 2.** EpCAM staining in prostate cancer tissue. Strong brown cytoplasmic staining for EpCAM in prostate cancer cells (arrows), 400× magnification.






**Figure 3.** VEGF staining in prostate cancer tissue. Strong brown cytoplasmic staining for VEGF in prostate cancer cells, 200× magnification.



**Figure 4.** GRPR staining in prostate cancer tissue. (a) Strong brown cytoplasmic staining for GRPR in prostate cancer cells and weak background staining of prostate stromal cells; (b) equal staining intensity of prostate cancer and stroma, 200× magnification.



### 2.3. Discussion

This study has shown that PSMA, EpCAM, VEGF and GRPR are expressed in locally recurrent prostate cancer after brachytherapy and external beam radiotherapy. Staining for PSMA and GRPR was observed in all prostate cancer specimens (17/17), while EpCAM and VEGF staining was observed in 82.3% (14/17) of cases (Tables 1 and 2). Staining for PSMA, EpCAM and VEGF was absent (0/17) in specimens' stromal compartments, while GRPR staining in stroma was observed in 100% (17/17) of cases. In 88.2% (15/17) of cases, the GRPR staining intensity of prostate cancer was equal to the staining intensity of stroma. Staining of striated muscle was observed for GRPR, which is in agreement with the findings of other groups [60–62].

The high expression of PSMA, EpCAM, VEGF and GRPR in locally recurrent prostate cancer after ionizing therapy could have several reasons, which will be postulated next. First, high expression of either antigen is correlated with a tendency for recurrence. This holds true for PSMA, as its expression in primary prostate cancer is positively correlated with factors, like a high Gleason grade, a higher tumor stage and, most important in this case, biochemical recurrence [11,18]. The same goes for EpCAM, as a recent study by Benko *et al.* showed that higher EpCAM expression correlated with a higher Gleason score and a shorter disease-free survival [34]. However, other research groups found conflicting results [26,30,65]. Expression of VEGF in prostate cancer positively correlated with high a Gleason score, lymph node metastases and the progression of disease [66]. Although there is no information about GRPR expression and recurrence, the process might be comparable.

Second is the upregulation of antigens due to radiotherapy. It has been demonstrated that VEGF is upregulated after radiotherapy for rectal cancer [67]. For EpCAM, PSMA and GRPR, this is currently unknown. Third, recurrent cancer could have the tendency for upregulation of certain antigens. In ovarian cancer, EpCAM upregulation was seen in recurrent cancer when compared to primary cancer in matched samples [68], while VEGF levels were significantly higher in recurrent acute lymphoblastic leukemia compared with newly diagnosed cases [69]. For all the postulations, we have no direct evidence, as we did not have prostate cancer biopsy samples before and after radiation therapy that could have been compared to the salvage prostatectomy samples.

The absence of non-specific background staining of normal tissue or prostate stroma for the anti-PSMA, EpCAM and VEGF antibodies proves the specificity for cancer tissue. Background staining for GRPR was evident. Although different protocols were used and different blocking agents were tested, staining of non-cancer tissue remained. Staining of normal prostate and muscle with the anti-GRPR antibody has been described in the literature by other authors [60–62], and at first glance, this might pose a problem for the future use of GRPR as a target for new therapeutic or diagnostic modalities. However, pre-clinical and clinical studies have shown very low uptake of GRPR-targeted bombesin-like radiopharmaceuticals in muscle with high tumor-to-muscle ratios [70].

The current study has several limitations. First, we did not have matched samples of prostate cancer tissue. In an ideal situation, we would have compared prostate biopsy samples at initial diagnosis before radiation therapy, the biopsy samples in which local recurrence was confirmed after radiation therapy and the salvage prostatectomy samples; Second, staining intensity was assessed qualitatively on a scale from zero to three. Although strong staining suggests a higher antigen density than weak staining does, it is impossible to make a comparison between the different antibodies used in this study, as different protocols were used and as there is most likely different antigen sensitivity for each antibody. A quantification of antigen-densities has to be performed to be able to make a comparison between antigens; Third, due to the low number of patients ( $n = 17$ ), the power of the statistics would be too weak, and therefore, we were unable to correlate staining intensity with clinicopathological parameters.

Finally, we did not have the follow-up data to compare antigen expression with outcome.

There is not much knowledge about the expression of antigens in recurrent prostate cancer. Locally recurrent prostate cancer is, to our knowledge, an unexplored field. Therefore, this is the first study to show the data about the expression of PSMA, VEGF, EpCAM and GRPR in locally recurrent prostate cancer after ionizing therapy.



Antigen-based targeted imaging of the prostate could be useful in several scenarios: if salvage local therapy was planned without a biopsy or with repeated negative biopsies, but with a strong suspicion of local recurrence. Other applications for these imaging strategies would be to rule out micrometastatic disease prior to local salvage therapy or the application of salvage focal therapy only to areas of uptake on imaging in order to minimize side-effects in irradiated tissue. The unique overexpression on prostate cancer cells makes PSMA the most attractive target for the delivery of imaging agents [10]. Several clinical studies with PSMA as the target have been reported with encouraging results [71,72]. Bombesin-like radiopharmaceuticals, which are natural ligands of GRPR, can be relatively easily synthesized in large quantities and have shown promising results in several clinical studies [70]. However, due to its background staining, more careful selection of the protocol may be required for optimal targeting. Only a few studies consider VEGF and EpCAM-based diagnostics for targeted cancer imaging [73–75], but based on the results reported in this study, both antigens can be used for the detection of locally recurrent prostate cancer.

### 3. Experimental Section

#### 3.1. Materials

Patients in our retrospective study were diagnosed with locally recurrent prostate cancer based on PSA relapse and transrectal ultrasound-guided prostate biopsies. Prostate cancer specimens were collected of 17 patients who underwent salvage prostatectomy (The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital Amsterdam (NKI/AVL)), because of locally recurrent prostate cancer after brachytherapy (4 patients) or external beam radiotherapy (13 patients). All tissue specimens were anonymous and encoded with a unique code. According to Dutch law, no further Institutional Review Board approval was required (<http://www.federa.org>). Pretreatment biopsies were not available.

#### 3.2. Immunohistochemistry

Formalin-fixed, paraffin-embedded blocks of prostate tissue were cut into 4-mm-thick sections and mounted on Starfrost microscope slides. Hematoxylin and eosin stained sections were graded by an experienced pathologist (Stefano Rosati), based on the criteria of the Gleason grading system. Remaining sections were processed for immunohistochemistry.

##### 3.2.1. PSMA

After deparaffinization, antigen retrieval was performed by heating microwave (700 W) for 20 min in a 10 mM citrate buffer at pH 6.0, with a cool down period of 20 min afterwards. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in phosphate-buffered saline (PBS) for 20 min. Slides were then incubated with the primary anti-human-PSMA mouse monoclonal antibody, YPSMA-1 (Abcam, Cambridge, UK), diluted at 1:400 in 1% bovine serum albumin/phosphate-buffered saline (1% BSA/PBS) for 1 h at room temperature. The secondary step consisted of incubation with rabbit anti-mouse antibody conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, Denmark), diluted at 1:100 in 1% BSA/PBS with 1% AB serum. For the tertiary step, goat anti-rabbit

antibody conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, Denmark) was used, diluted at 1:100 in 1% BSA/PBS with 1% AB serum. Both the secondary and tertiary step required incubation for 30 min at room temperature. Next, the slides were immersed for 10 min in a solution of 0.05% 3,3'-diaminobenzidine (Sigma-Aldrich, St. Louis, MO, USA) and 0.03% hydrogen peroxide in PBS for the visualization of the signal as brown staining. After washing with demineralized water, the slides were slightly counterstained with hematoxylin, dehydrated and mounted with Eukitt mounting medium (Sigma-Aldrich, Steinheim, Germany).

### 3.2.2. GRPR

After deparaffinization, antigen retrieval was performed by heating microwave (700 W) for 20 min in 0.1 M Tris/HCl buffer at pH 9.0, with a cool down period of 20 min afterwards. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in Tris-buffered saline (TBS) for 20 min. Slides were then incubated with a normal goat serum diluted at 1:10 in TBS for 30 min at room temperature. Afterwards, the slides were incubated with the primary anti-human-GRPR rabbit polyclonal antibody, ab39963 (Abcam, Cambridge, UK), diluted at 1:250 in 1% BSA/TBS overnight at 4 °C. Only a secondary step with goat anti-rabbit antibody conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, Denmark) was applied, diluted at 1:100 in 1% BSA/TBS with 1% AB serum for 60 min at room temperature. Next, the slides were immersed for 10 min in a solution of 0.05% 3,3'-diaminobenzidine (Sigma-Aldrich, Steinheim, Germany) and 0.03% hydrogen peroxide in PBS for the visualization of the signal as brown staining. After washing with demineralized water, the slides were slightly counterstained with hematoxylin, dehydrated and mounted with Eukitt mounting medium (Sigma-Aldrich, Steinheim, Germany).

### 3.2.3. EpCAM

After deparaffinization, antigen retrieval was performed by incubation with 0.1% protease for 30 min at room temperature. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in PBS for 20 min. Slides were then incubated with the primary mouse monoclonal anti-EpCAM antibody (Clone VU-1D9, Leica Biosystems, Newcastle, UK) diluted at 1:100 in 1% BSA/PBS for 1 h at room temperature. The secondary step consisted of incubation with rabbit anti-mouse antibody conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, Denmark), diluted at 1:100 in 1% BSA/PBS with 1% AB serum. For the tertiary step, goat anti-rabbit antibody conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, Denmark) was used, diluted at 1:100 in 1% BSA/PBS with 1% AB serum. Both the secondary and tertiary step required incubation for 30 min at room temperature. Next, the slides were immersed for 10 min in a solution of 0.05% 3,3'-diaminobenzidine (Sigma-Aldrich, Steinheim, Germany) and 0.03% hydrogen peroxide in PBS for visualization of the signal as brown staining. After washing with demineralized water, the slides were slightly counterstained with hematoxylin, dehydrated and mounted with Eukitt mounting medium (Sigma-Aldrich, Steinheim, Germany).

### 3.2.4. VEGF

After deparaffinization, microwave antigen retrieval (700 W) was performed for 20 min in 10 mM Tris/1 mM EDTA buffer at pH 9.0, with a cool down period of 20 min afterwards. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in PBS for 20 min. Slides were incubated with a normal goat serum diluted at 1:10 in PBS for 30 min at room temperature. The primary step consisted of incubation with rabbit anti-human antibody VEGF A-20 sc-152, (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted at 1:200 in 1% BSA/PBS for 1 h at room temperature. Only a secondary step with goat anti-rabbit antibody conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, Denmark) was applied, diluted at 1:100 in 1% BSA/TBS with 1% AB serum for 30 min at room temperature. Next, the slides were immersed for 10 min in a solution of 0.05% 3,3'-diaminobenzidine (Sigma-Aldrich, Steinheim, Germany) and 0.03% hydrogen peroxide in PBS for the visualization of the signal as brown staining. After washing with demineralized water, the slides were slightly counterstained with hematoxylin, dehydrated and mounted with Eukitt mounting medium (Sigma-Aldrich, Steinheim, Germany).

### 3.3. Assessment of Staining Patterns

The assessment of staining patterns was performed as described before [8]. For each antigen, a pathologist (Stefano Rosati) blinded to clinical and pathological data, scored the staining intensity (0 = no staining; 1+ = weak staining; 2+ = moderate staining; 3+ = strong staining) of tumor areas for all the specimens. Specimens in which one or more tumor areas with different staining intensities were present were scored for the most prevalent intensity. Specimens with focal uptake amidst negative cancer tissue scored 1+. Furthermore, different patterns of immunoreactivity were observed and documented. To evaluate background staining, all specimens were evaluated in a field that contained both prostate cancer and stroma. Tumor distinctiveness was assessed for each antigen by subtracting the staining intensity of stroma from the staining intensity of prostate cancer.

## 4. Conclusions

The current study is the first to present data on the expression of PSMA, EpCAM, VEGF and GRPR in locally recurrent prostate cancer after brachytherapy or external beam radiotherapy. Based on the absence of stromal staining, PSMA, EpCAM and VEGF show high tumor distinctiveness. GRPR has a very low tumor distinctiveness. Therefore, PSMA, EpCAM and VEGF can be used as targets for the bioimaging of recurrent prostate cancer after EBRT to exclude metastatic disease and/or to plan local salvage therapy.

## Acknowledgments

The Center for Translational Molecular Medicine, Project Prostate Cancer Molecular Medicine (03O-203), has financially contributed to the current research.

## Conflicts of Interest

The authors declare no conflict of interest.

## References

1. Center, M.M.; Jemal, A.; Lortet-Tieulent, J.; Ward, E.; Ferlay, J.; Brawley, O.; Bray, F. International variation in prostate cancer incidence and mortality rates. *Eur. Urol.* **2012**, *61*, 1079–1092.
2. Kupelian, P.A.; Potters, L.; Khuntia, D.; Ciezki, J.P.; Reddy, C.A.; Reuther, A.M.; Carlson, T.P.; Klein, E.A. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.* **2004**, *58*, 25–33.
3. Bellmunt, J.; Attard, G.; Bahl, A.; Huland, H.; Klotz, L.; Kuban, D.; Oudard, S.; Watson, W. Advances in the management of high-risk localised and metastatic prostate cancer. *BJU Int.* **2012**, *109*, 8–13.
4. Hillier, S.M.; Maresca, K.P.; Femia, F.J.; Marquis, J.C.; Foss, C.A.; Nguyen, N.; Zimmerman, C.N.; Barrett, J.A.; Eckelman, W.C.; Pomper, M.G.; *et al.* Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. *Cancer Res.* **2009**, *69*, 6932–6940.
5. Kularatne, S.A.; Wang, K.; Santhapuram, H.K.; Low, P.S. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. *Mol. Pharm.* **2009**, *6*, 780–789.
6. Entwistle, J.; Brown, J.G.; Chooniedass, S.; Cizeau, J.; MacDonald, G.C. Preclinical evaluation of VB6-845: An anti-EpCAM immunotoxin with reduced immunogenic potential. *Cancer Biother. Radiopharm.* **2012**, *27*, 582–592.
7. Köllermann, J.; Helpap, B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. *Am. J. Clin. Pathol.* **2001**, *116*, 115–121.
8. Ananias, H.J.; van den Heuvel, M.C.; Helfrich, W.; de Jong, I.J. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. *Prostate* **2009**, *69*, 1101–1108.
9. Bouchelouche, K.; Choyke, P.L.; Capala, J. Prostate specific membrane antigen—A target for imaging and therapy with radionuclides. *Discov. Med.* **2010**, *9*, 55–61.
10. Ghosh, A.; Heston, W.D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. *J. Cell. Biochem.* **2004**, *91*, 528–539.
11. Ross, J.S.; Sheehan, C.E.; Fisher, H.A.; Kaufman, R.P., Jr.; Kaur, P.; Gray, K.; Webb, I.; Gray, G.S.; Mosher, R.; Kallakury, B.V. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. *Clin. Cancer Res.* **2003**, *9*, 6357–6362.
12. Elsasser-Beile, U.; Buhler, P.; Wolf, P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. *Curr. Drug Targets* **2009**, *10*, 118–125.



13. Bouchelouche, K.; Capala, J. “Image and treat”—An individualized approach to urological tumors. *Curr. Opin. Oncol.* **2010**, *22*, 274–280.
14. Bostwick, D.G.; Pacelli, A.; Blute, M.; Roche, P.; Murphy, G.P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. *Cancer* **1998**, *82*, 2256–2261.
15. Lapidus, R.G.; Tiffany, C.W.; Isaacs, J.T.; Slusher, B.S. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. *Prostate* **2000**, *45*, 350–354.
16. Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N.H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. *Cancer Res.* **1997**, *57*, 3629–3634.
17. Silver, D.A.; Pellicer, I.; Fair, W.R.; Heston, W.D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. *Clin. Cancer Res.* **1997**, *3*, 81–85.
18. Minner, S.; Wittmer, C.; Graefen, M.; Salomon, G.; Steuber, T.; Haese, A.; Huland, H.; Bokemeyer, C.; Yekebas, E.; Dierlamm, J.; *et al.* High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. *Prostate* **2011**, *71*, 281–288.
19. Rajasekaran, A.K.; Anilkumar, G.; Christiansen, J.J. Is prostate-specific membrane antigen a multifunctional protein? *Am. J. Physiol. Cell Physiol.* **2005**, *288*, C975–C981.
20. Bermejo, C.E.; Coursey, J.; Basler, J.; Austenfeld, M.; Thompson, I. Histologic confirmation of lesions identified by ProstaScint scan following definitive treatment. *Urol. Oncol.* **2003**, *21*, 349–352; discussion 353.
21. Lau, H.Y.; Kindrachuk, G.; Carter, M.; Prestage, K.; Webber, D.; Stauffer, E.; Haseman, M. Surgical confirmation of ProstaScint abnormalities in two patients with high risk prostate cancer. *Can. J. Urol.* **2001**, *8*, 1199–1202.
22. Hinkle, G.H.; Burgers, J.K.; Olsen, J.O.; Williams, B.S.; Lamatrice, R.A.; Barth, R.F.; Rogers, B.; Maguire, R.T. Prostate cancer abdominal metastases detected with indium-111 capromab pendetide. *J. Nucl. Med.* **1998**, *39*, 650–652.
23. Manyak, M.J.; Hinkle, G.H.; Olsen, J.O.; Chiaccherini, R.P.; Partin, A.W.; Piantadosi, S.; Burgers, J.K.; Texter, J.H.; Neal, C.E.; Libertino, J.A.; *et al.* Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer. *Urology* **1999**, *54*, 1058–1063.
24. Taneja, S.S. ProstaScint<sup>®</sup> Scan: Contemporary use in clinical practice. *Rev. Urol.* **2004**, *6*, S19–S28.
25. Trzpis, M.; McLaughlin, P.M.; de Leij, L.M.; Harmsen, M.C. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. *Am. J. Pathol.* **2007**, *171*, 386–395.
26. Went, P.; Vasei, M.; Bubendorf, L.; Terracciano, L.; Tornillo, L.; Riede, U.; Kononen, J.; Simon, R.; Sauter, G.; Baeuerle, P.A. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate, and lung cancers. *Br. J. Cancer* **2006**, *94*, 128–135.
27. Van der Gun, B.T.; Melchers, L.J.; Ruiters, M.H.; de Leij, L.F.; McLaughlin, P.M.; Rots, M.G. EpCAM in carcinogenesis: The good, the bad, or the ugly. *Carcinogenesis* **2010**, *31*, 1913–1921.
28. Stoecklein, N.H.; Siegmund, A.; Scheunemann, P.; Luebke, A.M.; Erbersdobler, A.; Verde, P.E.; Eisenberger, C.F.; Peiper, M.; Rehders, A.; Esch, J.S.; *et al.* Ep-CAM expression in squamous cell carcinoma of the esophagus: A potential therapeutic target and prognostic marker. *BMC Cancer* **2006**, *6*, 165.

29. Went, P.T.; Lugli, A.; Meier, S.; Bundi, M.; Mirlacher, M.; Sauter, G.; Dirnhofer, S. Frequent EpCam protein expression in human carcinomas. *Hum. Pathol.* **2004**, *35*, 122–128.
30. Poczatek, R.B.; Myers, R.B.; Manne, U.; Oelschlager, D.K.; Weiss, H.L.; Bostwick, D.G.; Grizzle, W.E. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. *J. Urol.* **1999**, *162*, 1462–1466.
31. Varga, M.; Obrist, P.; Schneeberger, S.; Mühlmann, G.; Felgel-Farnholz, C.; Fong, D.; Zitt, M.; Brunhuber, T.; Schäfer, G.; Gastl, G.; *et al.* Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. *Clin. Cancer Res.* **2004**, *10*, 3131–3136.
32. Ni, J.; Cozzi, P.J.; Duan, W.; Shigdar, S.; Graham, P.H.; John, K.H.; Li, Y. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. *Cancer Metastasis Rev.* **2012**, *31*, 779–791.
33. Patriarca, C.; Macchi, R.M.; Marschner, A.K.; Mellstedt, H. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. *Cancer Treat. Rev.* **2012**, *38*, 68–75.
34. Benko, G.; Spajić, B.; Krušlin, B.; Tomas, D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. *Urol. Oncol.* **2013**, *31*, 468–474.
35. Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. *J. Mol. Med.* **1999**, *77*, 527–543.
36. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. *Nat. Med.* **2003**, *9*, 669–676.
37. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. *Endocr. Rev.* **2004**, *25*, 581–611.
38. Kaushal, V.; Mukunyadzi, P.; Dennis, R.A.; Siegel, E.R.; Johnson, D.E.; Kohli, M. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: Expression of lymphangiogenic markers is associated with advanced-stage disease. *Clin. Cancer Res.* **2005**, *11*, 584–593.
39. Peyromaure, M.; Badoual, C.; Camparo, P.; Grabar, S.; Goulvestre, C.; Fulla, Y.; Vieillefond, A.; Mao, K.; Dinh-Xuan, A.T. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer. *Oncol. Rep.* **2007**, *18*, 145–149.
40. Borre, M.; Nerstrøm, B.; Overgaard, J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. *Clin. Cancer Res.* **2000**, *6*, 1882–1890.
41. Jackson, M.W.; Bentel, J.M.; Tilley, W.D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. *J. Urol.* **1997**, *157*, 2323–2328.
42. Ferrer, F.A.; Miller, L.J.; Andrawis, R.I.; Kurtzman, S.H.; Albertsen, P.C.; Laudone, V.P.; Kreutzer, D.L. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: *In situ* and *in vitro* expression of VEGF by human prostate cancer cells. *J. Urol.* **1997**, *157*, 2329–2333.
43. El-Gohary, Y.M.; Silverman, J.F.; Olson, P.R.; Liu, Y.L.; Cohen, J.K.; Miller, R.; Saad, R.S. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. *Am. J. Clin. Pathol.* **2007**, *127*, 572–579.

44. Pasquali, D.; Rossi, V.; Staibano, S.; de Rosa, G.; Chieffi, P.; Prezioso, D.; Mirone, V.; Mascolo, M.; Tramontano, D.; Bellastella, A.; *et al.* The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy. *Endocrinology* **2006**, *147*, 4245–4251.
45. Pallares, J.; Rojo, F.; Iriarte, J.; Morote, J.; Armadans, L.I.; de Torres, I. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. *Histol. Histopathol.* **2006**, *21*, 857–865.
46. Walsh, K.; Sriprasad, S.; Hopster, D.; Codd, J.; Mulvin, D. Distribution of vascular endothelial growth factor (VEGF) in prostate disease. *Prostate Cancer Prostatic Dis.* **2002**, *5*, 119–122.
47. Kwak, C.; Jin, R.J.; Lee, C.; Park, M.S.; Lee, S.E. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. *BJU Int.* **2002**, *89*, 303–309.
48. Strohmeyer, D.; Rössing, C.; Bauerfeind, A.; Kaufmann, O.; Schlechte, H.; Bartsch, G.; Loening, S. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. *Prostate* **2000**, *45*, 216–224.
49. Mazzucchelli, R.; Montironi, R.; Santinelli, A.; Lucarini, G.; Pugnali, A.; Biagini, G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. *Prostate* **2000**, *45*, 72–79.
50. Mao, K.; Badoual, C.; Camparo, P.; Delongchamps, N.B.; Vieillefond, A.; Dinh-Xuan, A.T.; Peyromaure, M. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: A prospective evaluation in 100 patients undergoing radical prostatectomy. *Can. J. Urol.* **2008**, *15*, 4257–4262.
51. Boddy, J.L.; Fox, S.B.; Han, C.; Campo, L.; Turley, H.; Kanga, S.; Malone, P.R.; Harris, A.L. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF1a, HIF2a, and the prolyl hydroxylases in human prostate cancer. *Clin. Cancer Res.* **2005**, *11*, 7658–7663.
52. Jans, J.; van Dijk, J.H.; van Schelven, S.; van der Groep, P.; Willems, S.H.; Jonges, T.N.; van Diest, P.J.; Bosch, J.L. Expression and localization of hypoxia proteins in prostate cancer: Prognostic implications after radical prostatectomy. *Urology* **2010**, *75*, 786–792.
53. Mao, K.; Camparo, P.; Badoual, C.; Peyromaure, M.; Delongchamps, N.B.; Vieillefond, A.; Dinh-Xuan, A.T. The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy. *Oncol. Rep.* **2008**, *19*, 171–175.
54. Aprikian, A.G.; Cordon-Cardo, C.; Fair, W.R.; Reuter, V.E. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. *Cancer* **1993**, *71*, 3952–3965.
55. Cutz, E.; Chan, W.; Track, N.S. Bombesin, calcitonin and leu-enkephalin immunoreactivity in endocrine cells of human lung. *Experientia* **1981**, *37*, 765–767.
56. Price, J.; Penman, E.; Wass, J.A.; Rees, L.H. Bombesin-like immunoreactivity in human gastrointestinal tract. *Regul. Pept.* **1984**, *9*, 1–10.
57. Spindel, E.R.; Chin, W.W.; Price, J.; Rees, L.H.; Besser, G.M.; Habener, J.F. Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. *Proc. Natl. Acad. Sci. USA* **1984**, *81*, 5699–5703.

58. Track, N.S.; Cutz, E. Bombesin-like immunoreactivity in developing human lung. *Life Sci.* **1982**, *30*, 1553–1556.
59. Xiao, D.; Wang, J.; Hampton, L.L.; Weber, H.C. The human gastrinreleasing peptide receptor gene structure, its tissue expression and promoter. *Gene* **2001**, *264*, 95–103.
60. Beer, M.; Montani, M.; Gerhardt, J.; Wild, P.J.; Hany, T.F.; Hermanns, T.; Müntener, M.; Kristiansen, G. Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates. *Prostate* **2012**, *72*, 318–325.
61. Bartholdi, M.F.; Wu, J.M.; Pu, H.; Troncoso, P.; Eden, P.A.; Feldman, R.I. *In situ* hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. *Int. J. Cancer* **1998**, *79*, 82–90.
62. Markwalder, R.; Reubi, J.C. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. *Cancer Res.* **1999**, *59*, 1152–1159.
63. Bologna, M.; Festuccia, C.; Muzi, P.; Biordi, L.; Ciomei, M. Bombesin stimulates growth of human prostatic cancer cells *in vitro*. *Cancer* **1989**, *63*, 1714–1720.
64. Shimoda, J. Effects of bombesin and its antibody on growth of human prostatic carcinoma cell lines. *Nihon Hinyokika Gakkai Zasshi* **1992**, *83*, 1459–1468.
65. Zellweger, T.; Ninck, C.; Bloch, M.; Mirlacher, M.; Koivisto, P.A.; Helin, H.J.; Mihatsch, M.J.; Gasser, T.C.; Bubendorf, L. Expression patterns of potential therapeutic targets in prostate cancer. *Int. J. Cancer* **2005**, *113*, 619–628.
66. Li, R.; Younes, M.; Wheeler, T.M.; Scardino, P.; Otori, M.; Frolov, A.; Ayala, G. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. *Prostate* **2004**, *58*, 193–199.
67. Inoue, Y.; Ojima, E.; Watanabe, H.; Hiro, J.; Toiyama, Y.; Kobayashi, M.; Miki, C.; Kusunoki, M. Does preoperative chemo-radiotherapy enhance the expression of vascular endothelial growth factor in patients with rectal cancer? *Oncol. Rep.* **2007**, *18*, 369–375.
68. Bellone, S.; Siegel, E.R.; Cocco, E.; Cargnelutti, M.; Silasi, D.A.; Azodi, M.; Schwartz, P.E.; Rutherford, T.J.; Pecorelli, S.; Santin, A.D. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: Implications for epithelial cell adhesion molecule-specific immunotherapy. *Int. J. Gynecol. Cancer* **2009**, *19*, 860–866.
69. Koomagi, R.; Zintl, F.; Sauerbrey, A.; Volm, M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. *Clin. Cancer Res.* **2001**, *7*, 3381–3384.
70. Ananias, H.J.; de Jong, I.J.; Dierckx, R.A.; van de Wiele, C.; Helfrich, W.; Elsinga, P.H. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. *Curr. Pharm. Des.* **2008**, *14*, 3033–3047.
71. Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G.; Hadaschik, B.A.; Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Haufe, S.; *et al.* PET imaging with a [<sup>68</sup>Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. *Eur. J. Nucl. Med. Mol. Imaging* **2013**, *40*, 486–495.



72. Cho, S.Y.; Gage, K.L.; Mease, R.C.; Senthamizhchelvan, S.; Holt, D.P.; Jeffrey-Kwanisai, A.; Endres, C.J.; Dannals, R.F.; Sgouros, G.; Lodge, M.; *et al.* Biodistribution, tumor detection, and radiation dosimetry of <sup>18</sup>F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. *J. Nucl. Med.* **2012**, *53*, 1883–1891.
73. Cai, W.; Chen, X. Multimodality molecular imaging of tumor angiogenesis. *J. Nucl. Med.* **2008**, *49*, 113S–128S.
74. Hsieh, W.J.; Liang, C.J.; Chieh, J.J.; Wang, S.H.; Lai, I.R.; Chen, J.H.; Chang, F.H.; Tseng, W.K.; Yang, S.Y.; Wu, C.C.; *et al.* *In vivo* tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles. *Int. J. Nanomed.* **2012**, *7*, 2833–2842.
75. Song, Y.; Zhu, Z.; An, Y.; Zhang, W.; Zhang, H.; Liu, D.; Yu, C.; Duan, W.; Yang, C.J. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. *Anal. Chem.* **2013**, *85*, 4141–4149.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).